Tubulis

TubulisTubulis
Tubulis

Tubulis

Develops antibody-drug conjugates (ADCs) for targeted cancer therapy.

Website
DR 81Speed 482013Active118Munich, Germany
Rate
Advertise here

About

Tubulis generates uniquely matched antibody-drug conjugates (ADCs) with superior biophysical properties, demonstrating durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. Their lead programs, TUB-040 and TUB-030, are being evaluated in the clinic for high-need solid tumor indications. Tubulis aims to expand the therapeutic potential of ADCs for patients, partners, and through their pipeline.
Frequently asked

What does Tubulis do?

Tubulis generates uniquely matched antibody-drug conjugates (ADCs) with superior biophysical properties, demonstrating durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. Their lead programs, TUB-040 and TUB-030, are being evaluated in the clinic for high-need solid tumor indications. Tubulis aims to expand the therapeutic potential of ADCs for patients, partners, and through their pipeline.

What is Tubulis's valuation?

StartupHub estimates Tubulis's effective valuation at $1.8B (range $1.1B to $2.6B, 19% confidence), based on comparable companies in the sector.

How much funding has Tubulis raised?

Tubulis has raised a total of $437M in funding. The most recent round on record is Series C.

Where is Tubulis headquartered?

Tubulis is headquartered in Munich, Germany.

When was Tubulis founded?

Tubulis was founded in 2013.

What industry does Tubulis operate in?

Tubulis operates in BiTech, MedTech, HealthTech, Drug Discovery, Oncology, Antibody-Drug Conjugates.

How many employees does Tubulis have?

Tubulis has approximately 118 people on record.

HEADCOUNT
118
DOMAIN RATING
81
Comments

No comments yet. Be the first to share your take.